Sintilimab (IBI308) in the Neoadjuvant Treatment of Patients With Resectable II-IIIA NSCLC

Inclusion Criteria: 1. Age: 18 years old to 75 years old, male or female; 2. Histologically or cytologically confirmed NSCLC (stage II-IIIA, American Joint Committee on Cancer, eighth edition) that was surgically resectable; 3. Being treatment-naive and the diameter of primary tumor was greater than or equal to 1 cm; 4. ECOG performance status score: 0-1; 5. The function of important organs meets the following requirements (no blood components and cell growth factors are allowed for 2 weeks before the start of study): Absolute neutrophil count (ANC)≥1.5×10 E+9/L; platelets≥100×10E+9/L / L; hemoglobin ≥9g/dL; serum albumin(ALB)≥2.8g/dL; a total bilirubin (TBil) of≤1.5 ULN, ALT and AST≤2.5 ULN, in case of liver metastasis, ALT and AST≤5 ULN; creatinine clearance rate≥ 50mL/min(Cockcroft-Gault);thyroid function is normal. 6. Estimated survival time≥3 months; 7. PD-L1 expression level ≥ 1%； 8. Patients were voluntarily enrolled in the study and signed an informed consent form (ICF) with good adherence and follow-up. Exclusion Criteria: 1. The patient has any active autoimmune disease or a history of autoimmune disease; 2. The patient is using immunosuppressive agents or systemic hormonal therapy for immunosuppression purposes (dose\>10 mg / day of prednisone or other therapeutic hormones); 3. History of interstitial lung disease; 4. Severe allergic reactions to other monoclonal antibodies; 5. Previous allogeneic organ transplantation or hemopoietic stem cell transplantation; 6. Have clinical symptoms or disease that are not well controlled ; 7. Grade III to grade IV congestive heart failure; 8. Uncontrolled hypertension; 9. Artery thrombosis, embolism, or ischemia within 6 months before study treatment; 10. Coagulation disorders; 11. Active and uncontrolled infection; 12. The patient has previously received other PD-1 antibody therapy or other immunotherapy against PD-1/PD-L1; 13. Any other known malignant tumor;